The Effect of ACT and Tranexamic Acid on Bleeding in Cardiac Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Tranexamic acid.
- Who it may be relevant to
- Registry conditions: Surgery, Cardiac, Tranxemic Acid, Activated Clotting Time, Heparin. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Taiwan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Dose Effect of Activated Clotting Time and Tranexamic Acid on Bleeding in Adult Cardiac Surgery
Overview
The goal of this clinical trial is to the dose effect of tranexamic acid and the level of ACT on bleeding in adult cardiac surgery. The main questions it aims to answer are: 1. Does higher dose of tranexamic acid reduce the amount of bleeding and blood transfusion? 2. Does lower ACT level during cardiac surgery reduce the amount of bleeding and blood transfusion? Participants will divided into four groups which have different tranexamic acid dose and ACT level during cardiac surgery to see if there is any different in the amount of bleeding and blood transfusion.
Detailed description
This study is going to analyze the medical records of patients who underwent cardiac surgery between December 1, 2023, and December 31, 2026.
The investigators will categorize patients into four groups based on anticoagulation indices (ACT 400-600 seconds; ACT \> 600 seconds) and tranexamic acid dosages (low dose; high dose) within the range considered safe for CPB.
The primary outcome will be the volume of postoperative bleeding within 24 hours for each group.
The findings of this study will contribute to the existing clinical evidence and provide insights for the monitoring and pharmacological management in cardiac surgery.
Interventions
- Drug Tranexamic acid
tranexamic acid will be used in two different doses (50mg/kg vs 20mg/kg). the tranexamic acid pump will start from the begin of anesthesia until all dose is administrated.
Primary outcome measures
- Blood loss [Time frame: 24 hours]
- blood transfusion [Time frame: procedure time, an average of 6 hours]
Secondary outcome measures (1)
- 30-day mortality [Time frame: 30 days]
Eligibility criteria
Inclusion criteria
- adult, cardiac surgery with cardiopulmonary bypass
Exclusion criteria
- pregnant
- emergency procedure
- immune compromised
- aortic surgery
- end-stage renal disease
- liver disease
- critical status
- incomplete clinical data
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
Taiwan · 2 centers
- Taichung Veterans General Hospital — Taichung
- Taichung Veterans General hospital — Taichung
Identifiers
NCT: NCT06109155 · CF23323A